Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.85
+0.37 (4.36%)
At close: Aug 13, 2025, 4:00 PM
8.81
-0.04 (-0.45%)
After-hours: Aug 13, 2025, 7:59 PM EDT
Novavax Revenue
Novavax had revenue of $239.24M in the quarter ending June 30, 2025, a decrease of -42.42%. This brings the company's revenue in the last twelve months to $1.08B, up 9.22% year-over-year. In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%.
Revenue (ttm)
$1.08B
Revenue Growth
+9.22%
P/S Ratio
1.26
Revenue / Employee
$1,133,107
Employees
952
Market Cap
1.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NVAX News
- 7 days ago - Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Novavax beats quarterly revenue estimates on milestone payment - Reuters
- 7 days ago - Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 14 days ago - Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025 - PRNewsWire
- 20 days ago - Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates - Benzinga
- 20 days ago - Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study - PRNewsWire
- 2 months ago - Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study - Reuters